Sanofi and Regeneron secure stay of Praluent injunction
Sanofi and Regeneron have secured a stay of an injunction that would have blocked the companies from selling their cholesterol-lowering drug Praluent (alirocumab) injection.
The US Court of Appeals for the Federal Circuit stayed the injunction while Sanofi and Regeneron appeal an earlier order.
In January, LSIPR reported that the US District Court for the District of Delaware denied a motion to suspend the injunction, which was obtained by Amgen earlier that month.
Sanofi and Regeneron then revealed plans to bring the case to the Federal Circuit.
Amgen obtained the injunction after a finding that Praluent infringed Amgen’s patents covering the drug Repatha (evolocumab).
Sanofi and Regeneron will continue to market Praluent during the appeal process.
Karen Linehan, executive vice president and general counsel of Sanofi, said: “This decision is important for patients in the US, who will continue to have access to Praluent during the appeal process, giving them a choice in PCSK9 inhibitor treatments to best meet their individual needs.”
Joseph LaRosa, senior vice president of Regeneron, added: “We continue to believe the facts and controlling law support our position in this case. We will continue to vigorously defend our case through the appeal process.”
A number of physicians have backed Sanofi and Regeneron in their injunction appeal, filing amicus briefs at the Federal Circuit.
